"The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.
This first-of-its-kind use is"...
Patients receiving activated DEFINITY® should be instructed to inform their healthcare provider if they:
- have a congenital heart defect, or recent worsening of heart or lung conditions [see CONTRAINDICATIONS and WARNINGS AND PRECAUTION],
- have had prior reactions to DEFINITY® [see CONTRAINDICATIONS],
- may be pregnant, are trying to become pregnant, or are nursing [see Use In Specific Populations].
Last reviewed on RxList: 11/4/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Definity Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.